Interim Management Statement Q1 2020: Continued Progress on Abicipar, Sharpened Focus on Pipeline Activities
Zurich-Schlieren, Switzerland, May 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage
biotech company that is developing a new class of custom-built protein therapeutics known as
DARPin® therapeutics, announced today its interim management statement for the period ending
March 31, 2020.
“We have responded to the current global pandemic in three ways: ensuring the safety of our
employees and other stakeholders; preserving continuity of operations with appropriate safeguards;
and initiating an accelerated anti-COVID-19 program to leverage the compelling advantages of the
DARPin® platform against the novel coronavirus. As we prepare for the FDA’s decision regarding
abicipar, which would be the first approved DARPin® therapeutic, we have continued to progress our
broad pipeline of next-generation multi-DARPin® candidates,” said Patrick Amstutz, Ph.D., Chief
Executive Officer of Molecular Partners. “Our focus as ever is excellence in scientific innovation
executed by a team united by a common purpose to deliver an entirely new class of medicine.”